- Home
- Publications
- Publication Search
- Publication Details
Title
JNK, p38, ERK, and SGK1 Inhibitors in Cancer
Authors
Keywords
-
Journal
Cancers
Volume 10, Issue 1, Pages 1
Publisher
MDPI AG
Online
2017-12-22
DOI
10.3390/cancers10010001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The SGK1 inhibitor SI113 induces autophagy, apoptosis, and endoplasmic reticulum stress in endometrial cancer cells
- (2017) Domenico Conza et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1
- (2017) Sunbin Ling et al. Journal of Hematology & Oncology
- Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy
- (2017) Pablo Angulo et al. Journal of Hematology & Oncology
- Molecular modeling and structure-based drug discovery approach reveals protein kinases as off-targets for novel anticancer drug RH1
- (2017) Pramodkumar P. Gupta et al. MEDICAL ONCOLOGY
- KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma
- (2017) Jonas Cicenas et al. MEDICAL ONCOLOGY
- Regulation of intestinal myofibroblasts by KRas-mutated colorectal cancer cells through heparin-binding epidermal growth factor-like growth factor
- (2017) Hideyoshi Kawasaki et al. ONCOLOGY REPORTS
- Rac3 Regulates Cell Invasion, Migration and EMT in Lung Adenocarcinoma through p38 MAPK Pathway
- (2017) Chenlei Zhang et al. Journal of Cancer
- KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
- (2017) Jonas Cicenas et al. Cancers
- The potential role of Akt phosphorylation in human cancers
- (2017) J. Cicenas INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
- Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma
- (2017) Chengli Song et al. Scientific Reports
- The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer
- (2016) Xin Jin et al. CANCER BIOLOGY & THERAPY
- The Aurora kinase inhibitors in cancer research and therapy
- (2016) Jonas Cicenas JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Multi-kinase inhibitors, AURKs and cancer
- (2016) Jonas Cicenas et al. MEDICAL ONCOLOGY
- Effect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells
- (2016) Atiye Seda Yar Saglam et al. Oncology Letters
- The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo
- (2016) Masashi Okada et al. Oncotarget
- MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism
- (2016) Diane M. Pereira et al. Oncotarget
- SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells
- (2016) Cristina Talarico et al. Oncotarget
- Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents
- (2015) I. A. Vasilevskaya et al. CLINICAL CANCER RESEARCH
- A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- SP600125 promotes resolution of allergic airway inflammation via TLR9 in an OVA-induced murine acute asthma model
- (2015) Hui-Mei Wu et al. MOLECULAR IMMUNOLOGY
- Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
- (2015) Helen Gharwan et al. Nature Reviews Clinical Oncology
- SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways
- (2015) Elisa Stellaria Grassi et al. Oncotarget
- Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy
- (2015) Cristina Talarico et al. Oncotarget
- Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors
- (2015) Jalaj Gupta et al. Oncotarget
- Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin
- (2015) Jantine PosthumadeBoer et al. Oncotarget
- XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism
- (2014) Sripathi M. Sureban et al. CANCER LETTERS
- The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma
- (2014) Elisabetta Rovida et al. GUT
- c-Jun N-terminal kinase inhibitor SP600125 enhances barrier function and elongation of human pancreatic cancer cell line HPAC in a Ca-switch model
- (2014) Takumi Konno et al. HISTOCHEMISTRY AND CELL BIOLOGY
- In Silico Identification and Biological Evaluation of Novel Selective Serum/Glucocorticoid-Inducible Kinase 1 Inhibitors Based on the Pyrazolo-Pyrimidine Scaffold
- (2014) Francesco Ortuso et al. Journal of Chemical Information and Modeling
- Design and Synthesis of Highly Potent and Isoform Selective JNK3 Inhibitors: SAR Studies on Aminopyrazole Derivatives
- (2014) Ke Zheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy and Safety of AM-111 in the Treatment of Acute Sensorineural Hearing Loss
- (2014) Markus Suckfuell et al. OTOLOGY & NEUROTOLOGY
- Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer
- (2014) Xin-Juan Fan et al. TUMOR BIOLOGY
- Highlights of the Latest Advances in Research on CDK Inhibitors
- (2014) Jonas Cicenas et al. Cancers
- Mesothelioma Cell Proliferation through Autocrine Activation of PDGF- �� Receptor
- (2013) Miki Honda et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition
- (2013) Ju-Hwa Kim et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- ERK 5/MAPK pathway has a major role in 1α,25-(OH)2 vitamin D3-induced terminal differentiation of myeloid leukemia cells
- (2013) Xuening Wang et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
- (2013) R. M. Campbell et al. MOLECULAR CANCER THERAPEUTICS
- JNK inhibitor SP600125 enhances TGF-β-induced apoptosis of RBE human cholangiocarcinoma cells in a Smad-dependent manner
- (2013) YOUZHI LIN et al. Molecular Medicine Reports
- The specific, reversible JNK inhibitor SP600125 improves survivability and attenuates neuronal cell death in experimental cerebral malaria (ECM)
- (2013) Sripada Santosh Anand et al. PARASITOLOGY RESEARCH
- BIRB796, the Inhibitor of p38 Mitogen-Activated Protein Kinase, Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression Cells
- (2013) Dan He et al. PLoS One
- BIRB 796 has Distinctive Anti-inflammatory Effects on Different Cell Types
- (2013) Soyoon Ryoo et al. Immune Network
- Small molecule inhibitors of the c-Jun N-terminal kinase (JNK) possess antiviral activity against highly pathogenic avian and human pandemic influenza A viruses
- (2012) Wolfgang Nacken et al. BIOLOGICAL CHEMISTRY
- Selective killing of p53-deficient cancer cells by SP600125
- (2012) Mohamed Jemaà et al. EMBO Molecular Medicine
- Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors
- (2012) Marco Ragusa et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Kinase Control Prevents HIV-1 Reactivation in Spite of High Levels of Induced NF-κB Activity
- (2012) Frank Wolschendorf et al. JOURNAL OF VIROLOGY
- Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome
- (2012) L Sokol et al. LEUKEMIA
- Rosiglitazone and AS601245 Decrease Cell Adhesion and Migration through Modulation of Specific Gene Expression in Human Colon Cancer Cells
- (2012) Angelo Cerbone et al. PLoS One
- AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells
- (2012) Angelo Cerbone et al. PPAR Research
- MEK5/ERK5 pathway: The first fifteen years
- (2011) Barbara A. Drew et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase
- (2011) Shaun R. Selness et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The CDK inhibitors in cancer research and therapy
- (2011) Jonas Cicenas et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Novel p38α Mitogen-Activated Protein Kinase Inhibitor Shows Analgesic Efficacy in Acute Postsurgical Dental Pain
- (2011) Sandra E. Tong et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis
- (2011) MARK C. GENOVESE et al. JOURNAL OF RHEUMATOLOGY
- Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein
- (2010) Qingkai Yang et al. CANCER CELL
- The JNK inhibitor SP600125 enhances dihydroartemisinin-induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cells
- (2010) Ying-Ying Lu et al. FEBS LETTERS
- JNK signalling in human and experimental renal ischaemia/reperfusion injury
- (2010) J. Kanellis et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor
- (2010) Jonas Cicenas et al. Cancers
- SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin
- (2009) Ju-Hwa Kim et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model
- (2009) Yong-Jing Gao et al. EXPERIMENTAL NEUROLOGY
- Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat
- (2009) Frank Y Ma et al. LABORATORY INVESTIGATION
- Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells
- (2009) J. Cui et al. MOLECULAR CANCER THERAPEUTICS
- p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications
- (2008) Kenji Ishitsuka et al. BRITISH JOURNAL OF HAEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More